EDIT Editas Medicine
- 5.470
- +0.260+4.99%
- 5.540
- +0.070+1.28%
Editas Medicine News
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb
EDIT, CLNE and NIU Are Among After Hour Movers
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Editas Medicine, Inc. (NASDAQ:EDIT) shares are down a considerable 25% in the last month, which continues a horrid run for the company. Instead of being rewar
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in Vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one
Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx
Possible Bearish Signals With Editas Medicine Insiders Disposing Stock
The fact that multiple Editas Medicine, Inc. (NASDAQ:EDIT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When evaluating in
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
Biotech Roundtable: Is CRISPR All Its Cracked up to Be?
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Editas Medicine, Inc. (NASDAQ:EDIT) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month, although it is still struggling to make up recently lost ground.
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)
Insider Sells Shares of Editas Medicine Inc (EDIT)
Editas Medicine (EDIT) Receives a New Rating From a Top Analyst
1 Beaten-Down Stock With 55% Upside, According to Wall Street
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Editas Medicine, Inc. (NASDAQ:EDIT) just released its latest annual results and things are looking bullish. Results clearly exceeded expectations, with a substantial revenue beat leading to small
Editas Medicine Price Target Raised to $16.00/Share From $11.00 by Citigroup
Editas Medicine Price Target Raised to $16.00/Share From $11.00 by Citigroup
Editas Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/29/2024 48.84% Citigroup $11 → $16 Maintains Buy 02/29/2024 2.33% Barclays $10 → $11 Maintains Equal-We
Analysis
Price Target
No Data
